Harrow

HROW · NASDAQ

$28.07+$0.39 (+1.41%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $27.68

Latest news

Press releaseOct 5, 7:00 AM ETGlobe Newswire
Harrow Closes Acquisition of TYRVAYA®
Press releaseSep 30, 7:00 AM ETGlobe Newswire
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
NewsSep 25, 4:19 PM ETChandrima Sanyal
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
NewsAug 21, 12:09 PM ETVandana Singh
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half
Press releaseAug 20, 7:00 AM ETGlobe Newswire
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
NewsAug 11, 8:04 AM ETAvi Kapoor
OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
NewsAug 10, 4:08 PM ET
Harrow Q2 EPS $(0.46) Misses $(0.21) Estimate, Sales $70.661M Beat $70.342M Estimate
Press releaseAug 10, 4:05 PM ETGlobe Newswire
Harrow Announces Second Quarter 2026 Financial Results
NewsAug 6, 1:56 PM ETVandana Singh
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Press releaseAug 6, 7:00 AM ETGlobe Newswire
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Press releaseJul 20, 8:00 AM ETGlobe Newswire
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
Press releaseJul 20, 7:00 AM ETGlobe Newswire
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Press releaseJul 1, 7:00 AM ETBusiness Wire
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
Press releaseJul 1, 7:00 AM ETGlobe Newswire
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
NewsJun 11, 11:42 AM ETVandana Singh
Harrow Adds Another Piece To Ophthalmology Strategy
Press releaseJun 10, 7:00 AM ETGlobe Newswire
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
NewsMay 28, 12:18 PM ETTim Melvin
Alpha Buying: When CEOs and CFOs Buy Together
Press releaseMay 13, 10:13 AM ETGlobe Newswire
HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations
NewsMay 12, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMay 12, 11:29 AM ET
Transcript: Harrow Q1 2026 Earnings Conference Call
NewsMay 12, 8:03 AM ETAvi Kapoor
AST SpaceMobile Posts Downbeat Q1 Results, Joins Hims & Hers Health, Gitlab And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
NewsMay 12, 6:05 AM ETAvi Kapoor
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
NewsMay 11, 5:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseApr 16, 7:00 AM ETGlobe Newswire
Harrow Announces the Issuance of J-Code for IOPIDINE® 1%
Press releaseApr 14, 10:30 AM ETPRNewswire
LogiCare3PL Selected as Distribution Partner by Harrow
NewsMar 3, 12:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMar 3, 7:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsFeb 27, 1:02 PM ET
A Preview Of Harrow's Earnings
Press releaseFeb 3, 5:00 AM ETBusiness Wire
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
Press releaseNov 10, 4:05 PM ETGlobe Newswire
Harrow Announces Third Quarter 2025 Financial Results
NewsSep 23, 4:01 PM ET
Demystifying Harrow: Insights From 5 Analyst Reviews
Press releaseSep 15, 7:00 AM ETGlobe Newswire
Harrow Announces Agenda and Speakers for Investor & Analyst Day
Press releaseAug 16, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Press releaseAug 13, 12:05 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Press releaseAug 11, 4:01 PM ETGlobe Newswire
Harrow Announces Second-Quarter 2025 Financial Results
Press releaseAug 11, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Press releaseAug 6, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Press releaseAug 5, 10:00 AM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Press releaseAug 1, 10:00 AM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Press releaseJul 31, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Press releaseJul 28, 12:12 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Press releaseJul 27, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Press releaseJul 22, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW
Press releaseJul 18, 12:00 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW
Press releaseMay 8, 4:01 PM ETBusiness Wire
Harrow Announces First-Quarter 2025 Financial Results
Press releaseMar 27, 4:01 PM ETBusiness Wire
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
Press releaseNov 13, 4:34 PM ETBusiness Wire
Harrow Announces Third Quarter 2024 Financial Results
Press releaseAug 7, 4:01 PM ETBusiness Wire
Harrow Announces Second Quarter 2024 Financial Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Harrow Closes Acquisition of TYRVAYA®

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Harrow Q2 EPS $(0.46) Misses $(0.21) Estimate, Sales $70.661M Beat $70.342M Estimate

Harrow Announces Second Quarter 2026 Financial Results

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Harrow Adds Another Piece To Ophthalmology Strategy

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Alpha Buying: When CEOs and CFOs Buy Together

HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations

12 Health Care Stocks Moving In Tuesday's Intraday Session

Transcript: Harrow Q1 2026 Earnings Conference Call

AST SpaceMobile Posts Downbeat Q1 Results, Joins Hims & Hers Health, Gitlab And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Monday's After-Market Session

Harrow Announces the Issuance of J-Code for IOPIDINE® 1%

LogiCare3PL Selected as Distribution Partner by Harrow

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

A Preview Of Harrow's Earnings

OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California

Harrow Announces Third Quarter 2025 Financial Results

Demystifying Harrow: Insights From 5 Analyst Reviews

Harrow Announces Agenda and Speakers for Investor & Analyst Day

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

Harrow Announces Second-Quarter 2025 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. - HROW

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW

Harrow Announces First-Quarter 2025 Financial Results

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow Announces Third Quarter 2024 Financial Results

Harrow Announces Second Quarter 2024 Financial Results